Company intelligence / Profile preview
Axceso Biopharma
Gyeonggi-do, South Koreaaxcesobiopharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
The company's programs remain in the preclinical phase; published clinical data includes an AXL kinase inhibitor demonstrating antitumor activity in triple-negative breast cancer models. Patent literature focuses on immunomodulatory compositions for dementia and Parkinson’s disease, with no clinical-stage assets yet reported.
- Therapeutic areas
- OncologyNeurology
- Modalities
- Small molecule drugBiologic
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Axceso Biopharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Axceso Biopharma.